111 related articles for article (PubMed ID: 12494768)
21. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
Smythe WR; Mohuiddin I; Ozveran M; Cao XX
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
[TBL] [Abstract][Full Text] [Related]
22. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers.
Kitamura S; Kondo S; Shinomura Y; Kanayama S; Miyazaki Y; Kiyohara T; Hiraoka S; Matsuzawa Y
Br J Cancer; 2000 Sep; 83(5):668-73. PubMed ID: 10944610
[TBL] [Abstract][Full Text] [Related]
23. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines.
Li Z; Li Q; Han L; Tian N; Liang Q; Li Y; Zhao X; Du C; Tian Y
Oncol Rep; 2016 Feb; 35(2):1013-9. PubMed ID: 26718027
[TBL] [Abstract][Full Text] [Related]
24. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
25. [Up-expression of IL-6 and down-expression of TNFalpha may be involved in the regulation of apoptosis induced by antisense bcl-2 oligodeoxynucleotides].
Chen X; Hu J; Chen Z; Lu L
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Dec; 19(6):495-8. PubMed ID: 12476423
[TBL] [Abstract][Full Text] [Related]
26. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
[TBL] [Abstract][Full Text] [Related]
27. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Sierakowska H; Sambade MJ; Agrawal S; Kole R
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12840-4. PubMed ID: 8917506
[TBL] [Abstract][Full Text] [Related]
28. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.
Errington SJ; Mann CJ; Fletcher S; Wilton SD
J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117
[TBL] [Abstract][Full Text] [Related]
29. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors.
Sun L; Fuselier JA; Murphy WA; Coy DH
Peptides; 2002 Sep; 23(9):1557-65. PubMed ID: 12217415
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
31. Antisense approaches in prostate cancer.
Chi KN; Gleave ME
Expert Opin Biol Ther; 2004 Jun; 4(6):927-36. PubMed ID: 15174974
[TBL] [Abstract][Full Text] [Related]
32. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells.
Guensberg P; Wacheck V; Lucas T; Monia B; Pehamberger H; Eichler HG; Jansen B
Chemotherapy; 2002 Sep; 48(4):189-95. PubMed ID: 12218266
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
34. RNA-Mediated Disease Mechanisms in Neurodegenerative Disorders.
Neueder A
J Mol Biol; 2019 Apr; 431(9):1780-1791. PubMed ID: 30597161
[TBL] [Abstract][Full Text] [Related]
35. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
37. Antisense inhibition of membrane-bound human interleukin-5 receptor-alpha chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells.
Karras JG; McKay RA; Lu T; Dean NM; Monia BP
Antisense Nucleic Acid Drug Dev; 2000 Oct; 10(5):347-57. PubMed ID: 11079574
[TBL] [Abstract][Full Text] [Related]
38. Chimeric peptide nucleic acid compounds modulate splicing of the bcl-x gene in vitro and in vivo.
Wilusz JE; Devanney SC; Caputi M
Nucleic Acids Res; 2005; 33(20):6547-54. PubMed ID: 16299354
[TBL] [Abstract][Full Text] [Related]
39. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
40. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
